Abstract
Background Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.
Objective This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through February 25, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).
Methods Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and February 25, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.
Results We included 483,928 hospitalizations of 449,124 unique patients who tested positive for a respiratory virus between October 01, 2019 and February 25, 2024.
Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout February 2024 (-20.0%) compared to January 2024. While the main contributors COVID- and influenza-associated hospitalizations decreased (-26.5% and - 22.7%), all other respiratory viruses increased, with HMPV increasing quickly (117.2%). For infants and children, the overall and individual rate of hospitalization decreased. Rhinovirus-associated hospitalizations account for the largest percentage of hospitalizations with 1.2% in the last week of February 2024. The population over 65 years of age also saw an overall decrease in respiratory virus-associated hospitalizations (-19.9%) like the overall population. However, HMPV-associated hospitalizations increased rapidly (+204.6%).
Discussion We continue to see evidence that respiratory virus-associated hospitalizations peaked at end of 2023 and continue to decrease overall, including for the two high-risk populations we studied. In February 2024, rhinovirus-associated hospitalizations were the main respiratory virus contributing to hospitalizations for infants and children, while COVID-associated hospitalizations were the largest contributor for the older adult population. However, HMPV-associated hospitalization rose quickly in the older adult population, and we will continue to monitor its trends in the upcoming month.
Overall populationOverall, the rate of hospitalizations associated with respiratory viruses decreased throughout February 2024 (20.0% decrease since end of January 2024). This is due to the decrease in COVID-(-26.5%) and influenza-associated hospitalizations (-22.7%). Hospitalizations for all other monitored respiratory viruses increased, including those associated with HPMV, which more than doubled (+117.2%) throughout the month. COVID- and influenza-associated hospitalizations make up 2.3% and 1.7% of all hospitalizations, respectively. Other respiratory viruses studied each make up less than 1% of hospitalizations. Nevertheless, in the last week of February 2024, respiratory virus-associated hospitalizations accounted for 4.0% of all hospitalizations.
Infants and children (age 0-4)For the population between 0-4 years old, respiratory virus-associated hospitalizations decreased throughout February (-28.4%). For individual viruses, associated hospitalizations decreased when counts were above reporting thresholds. In the last week of February, 2.8% of all hospitalizations in this age group were associated with a respiratory virus, and rhinovirus-associated hospitalizations were the largest individual contributor (1.2%).
Older adults (age 65 and over)In the population over 65 years of age, there was a 19.9% decrease in hospitalizations associated with respiratory viruses. COVID-, influenza-, and RSV-associated hospitalizations all continued to decrease throughout the month, while HPMV-, parainfluenza-, and rhinovirus-associated hospitalizations all increased. HMPV-associated hospitalizations increased by 204.6% compared to the last week of January. In the last week of February, 5.2% of all hospitalizations in this age group were associated with a respiratory virus.
Competing Interest Statement
All authors are employees of Truveta, Inc
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We included updated data till end of February 2024.
Data Availability
The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.
